Children's Hospital Los Angeles
chla.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
148
Active
50
Phase 3
6
Total enrollment
27,282
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | — | — | — | 1 | |
| Randomization of Propofol or Dexmedetomidine | — | — | — | — | — | 1 | |
| Feiba | — | — | — | — | — | 1 | |
| Ferric derisomaltose | — | — | — | — | — | 1 | |
| NovaFerrum | — | — | — | — | — | 1 | |
| Fluoxetine | — | — | — | — | — | 1 | |
| Maralixibat 9.5 MG/ML [Livmarli] | — | — | — | — | — | 1 | |
| Semaglutide 2.4 mg | — | — | — | — | — | 1 | |
| Butyrate | — | — | — | — | — | 1 | |
| Crizanlizumab | — | — | — | — | — | 1 | |
| Dinutuximab with Chemotherapy | — | — | — | — | — | 1 |
Next readouts
- 2022-10
- 2025-02-23
- 2026-01
- 2026-04-01
- 2027-06-30
- 2027-06-30
- 2028-07-01
- 2028-09-01
- 2028-09-01
- 2030-11-01
Top conditions
- Pediatric Obesity6
- Medication Adherence5
- Sickle Cell Disease5
- Pain5
- Type 2 Diabetes4
- Anxiety4
- Quality of Life3
- Adolescent Idiopathic Scoliosis3
Frequently asked questions about Children's Hospital Los Angeles
- How many clinical trials does Children's Hospital Los Angeles have on ClinicalTrials.gov?
- Children's Hospital Los Angeles is listed as the lead sponsor on 148 clinical trials in ClinicalTrials.gov, 50 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Children's Hospital Los Angeles's trials are in Phase 3?
- 6 of Children's Hospital Los Angeles's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does Children's Hospital Los Angeles focus on?
- Children's Hospital Los Angeles's most-studied conditions on ClinicalTrials.gov are Pediatric Obesity, Medication Adherence, Sickle Cell Disease, Pain, Type 2 Diabetes.
- When are Children's Hospital Los Angeles's next clinical trial readouts?
- Children's Hospital Los Angeles has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab”, expected around 2022-10.